Compare Amgen, Inc. (AMGN) vs Intel Corp (INTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Intel Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Intel Corp trades at $107.01 (market cap $552.06B). The key difference: Intel Corp is far larger — about 2.8× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | INTC | |
|---|---|---|
Market Cap | $196.12B | $552.06B |
Sector | Health | Technology |
52-Week High | $388.16 | $140.94 |
52-Week Low | $271.18 | $19.31 |
Enterprise Value | $241.41B | $564.30B |
Dividend Yield | 2.77% | 2.24% |
Volume | — | 43,552,012 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Intel (INTC) trades at $109.84, down 2.4% on the day, with a bearish technical signal but recent earnings beats. The stock shows mixed fundamentals with a high P/E of 904.17 and negative net margin of -5.9%, though operating cash flow improved to $9.70B in 2025. News highlights government support and turnaround progress, with consensus price target at $99.70.
Outlook remains cautious due to profitability challenges and competitive pressures, but long-term growth potential exists from AI and foundry expansions. Key risks include execution on capital investments and market share loss to AMD. Analyst sentiment is mixed with 36.9% buy ratings, suggesting patience for turnaround results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
